Back to News
Market Impact: 0.7

Asian Shares Muted After Tuesday's Relief Rally

USDGLDUSONDAQDIASPY
Market Technicals & FlowsMonetary PolicyInterest Rates & YieldsGeopolitics & WarEconomic DataInflationCurrency & FXEnergy Markets & Prices
Asian Shares Muted After Tuesday's Relief Rally

Asian equities exhibited mixed performance Wednesday, largely consolidating previous gains, as a U.S.-brokered Israel-Iran ceasefire held despite ongoing Gaza conflict. U.S. markets rallied overnight, with major indices reaching four-month highs, buoyed by the geopolitical de-escalation and Federal Reserve Chair Powell's balanced remarks hinting at potential rate cuts by September if inflation and labor data weaken. Regional highlights included significant gains in China and Hong Kong, modest advances in Japan and Australia—where slowing inflation supports a likely RBA rate cut—while Olympus Corp. shares fell following an FDA import alert.

Analysis

Global equity markets are exhibiting a risk-on tone, driven by a fragile U.S.-brokered ceasefire between Israel and Iran and increasingly dovish central bank expectations. In the U.S., major indices including the S&P 500 (+1.1%) and the tech-heavy Nasdaq (+1.4%) reached four-month highs as Federal Reserve Chair Jerome Powell's balanced commentary led traders to price in potential rate cuts beginning in September. This sentiment, coupled with a weaker U.S. dollar, fueled significant rallies in Asian markets, with China's Shanghai Composite surging 1.04% and Hong Kong's Hang Seng jumping 1.23% on expectations of capital inflows. Japanese equities also saw modest gains, with the Nikkei rising 0.39% led by chip-related stocks like Advantest and Tokyo Electron which surged over 3%. In Australia, softer-than-expected inflation data has solidified expectations for a Reserve Bank of Australia rate cut next month. However, regional performance was not uniform, as New Zealand's benchmark extended losses for a sixth consecutive session and South Korea's market faces headwinds from MSCI's decision to delay its reclassification to developed status. Company-specific events also created significant divergence, illustrated by the 10.6% plunge in Olympus Corp. shares after the FDA issued an import alert on its medical devices.

AllMind AI Terminal

AI-powered research, real-time alerts, and portfolio analytics for institutional investors.